About this trial
Atrial fibrillation is the most common heart rhythm disorder (arrhythmia) worldwide. Nearly 40 million people are affected by atrial fibrillation worldwide, and this number is expected to increase by over 50% by 2050. Atrial fibrillation can cause strokes, heart attacks, heart failure, poor quality of life and even death. Almost half a million deaths worldwide are expected to be related to atrial fibrillation by 2050, and many billions of dollars are spent on atrial fibrillation related healthcare in North America every year.
We believe health outcomes for patients with atrial fibrillation, and healthcare costs associated with treating atrial fibrillation could be improved by optimizing existing treatments for atrial fibrillation and maximizing the likelihood of restoring normal heart rhythm. This allows them to benefit from lower stroke risk, better heart function, fewer symptoms and increased quality of life. Restoring normal sinus rhythm earlier prevents atrial fibrillation from causing permanent structural damage to the heart that in turn, makes atrial fibrillation intractable. Furthermore, patients in whom initial attempts to control atrial fibrillation are unsuccessful frequently require more medications or invasive catheter ablation procedures which are costly and carry substantial risk.
Electrical cardioversion is the main way physicians restore normal heart rhythm. In this procedure, the heart is "shocked" back into normal rhythm using two electrodes on the chest. Done correctly, this procedure is safe and effective. Many things are known about electrical cardioversion, for example, the best type and amount of electricity to use. What we don't know is the best position of the electrodes on the chest and whether applying direct, physical pressure to the electrodes makes cardioversion more successful. Our prior research suggests that improving positioning and applying pressure may improve cardioversion, but this finding needs to be verified with a rigorous, dedicated trial.
This study will demonstrate whether front-to-back, or front-to-side placement of the electrodes is more effective for electrical cardioversion of atrial fibrillation. We will also demonstrate whether manually applying pressure to the electrodes makes cardioversion more effective. Should our trial demonstrate a benefit for these techniques, we expect them to be universally applied around the world. Because hundreds of thousands of cardioversions are done each year, even small increases in cardioversion success means thousands fewer patients progress to needing more medications or invasive procedures to manage their atrial fibrillation.
We will study consenting adults presenting for non-urgent cardioversion of their atrial fibrillation. After explaining the study to participants and gaining their consent, we will randomly assign them to front-to-side or front-to-back electrode placement. Patients who remain in atrial fibrillation after the first shock will randomly receive either manual pressure or not. We will compare the success of cardioversion for front-side versus front-back electrode placement, and for manual pressure versus none. We will evaluate success by using electrocardiograms to assess for restoration of the heart rhythm back to normal.
We hypothesize that anterolateral electrode positioning is superior to anteroposterior electrode positioning. We also hypothesize that manual pressure is effective relative to none, when applied in patients who have had one unsuccessful shock already.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
Insufficiently anticoagulation for cardioversion as per Canadian Cardiovascular Society guidelines or have not undergone trans-esophageal echocardiography to rule out left atrial thrombus
Anatomic contraindication to anterolateral or anteroposterior placement (e.g. skin conditions or wounds)
Trial design
Parallel
Treatments tested in this trial
Anterolateral electrode position
Other interventionAs described previously
Anteroposterior electrode position
Other interventionAs described previously
Manual pressure
Other interventionManual pressure applied to the anterior electrode
Treatment groups
Trial outcomes
Primary outcomes
First-shock cardioversion success
Reversion to sinus rhythm (5 consecutive P waves within 5 seconds of shock)
Secondary outcomes
Cumulative cardioversion success for anterolateral versus anteroposterior placement afte
Reversion to sinus rhythm (5 consecutive P waves within 5 seconds of shock)
Second shock success for manual pressure versus none
Reversion to sinus rhythm (5 consecutive P waves within 5 seconds of shock)
Other outcomes
Descriptive analysis of techniques and results for third, unrandomized, clinician directed shock
Reversion to sinus rhythm (5 consecutive P waves within 5 seconds of shock)
First shock cardioversion success (subgroup analysis) by electrode position
As above; exploratory subgroup analysis of: Males vs females, BMI \> 30 vs BMI \< 30, First episode atrial fibrillation versus recurrent, Duration of current episode \>30 days vs \<30 days, Left ventricular ejection fraction \> 40% vs \<40%, Left atrial volume index \>34ml/m2 vs not, Premedication with amiodarone , sotalol or class 1 antiarrhythmic drugs versus not, History of cardiac surgery versus not
Second shock cardioversion success by manual pressure versus none
As above; exploratory subgroup analysis of: Males vs females, BMI \> 30 vs BMI \< 30, First episode atrial fibrillation versus recurrent, Duration of current episode \>30 days vs \<30 days, Left ventricular ejection fraction \> 40% vs \<40%, Left atrial volume index \>34ml/m2 vs not, Premedication with amiodarone , sotalol or class 1 antiarrhythmic drugs versus not, History of cardiac surgery versus not
Total number of shocks by electrode positioning
Reversion to sinus rhythm (5 consecutive P waves within 5 seconds of shock)
Sponsors and contacts
Click on the lead sponsor to view all of their trials.